Home › Overweight › Washington › Bellevue
Overweight clinical trials in Bellevue, WA
4 studies for Overweight are looking for participants at sites in and around Bellevue (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RecruitingPhase 2
- Northwest Clinical Research Center, Bellevue
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
RecruitingPhase 4
- Bellevue Dermatology Clinic, Bellevue
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
RecruitingPhase 3
- Northwest Clinical Research Center, Bellevue
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
RecruitingPhase 3
- Northwest Clinical Research Center, Bellevue
Overweight trials in other cities
- San Antonio, TX34 studies
- Houston, TX33 studies
- Chicago, IL27 studies
- Orlando, FL25 studies
- Miami, FL23 studies
- Las Vegas, NV22 studies
- Atlanta, GA21 studies
- Dallas, TX20 studies
- Washington, DC19 studies
- Austin, TX19 studies
- New York City, NY19 studies
- Jacksonville, FL18 studies
Other studies in Bellevue
- Major Depressive Disorder9 studies
- Obesity6 studies
- Alzheimer's Disease5 studies
- Ulcerative Colitis5 studies
- Schizophrenia5 studies
- Depression5 studies
- Crohn's Disease4 studies
- Knee Osteoarthritis4 studies
- Bipolar Disorder4 studies
- Steatotic Liver Disease3 studies
- Generalized Anxiety Disorder3 studies
- Psychotic Disorders3 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.